CN116712523B - 一种治疗中虚气逆型反流性食管炎组合物及其制备方法 - Google Patents
一种治疗中虚气逆型反流性食管炎组合物及其制备方法 Download PDFInfo
- Publication number
- CN116712523B CN116712523B CN202310788417.8A CN202310788417A CN116712523B CN 116712523 B CN116712523 B CN 116712523B CN 202310788417 A CN202310788417 A CN 202310788417A CN 116712523 B CN116712523 B CN 116712523B
- Authority
- CN
- China
- Prior art keywords
- parts
- reflux esophagitis
- deficiency
- stomach
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000021302 gastroesophageal reflux disease Diseases 0.000 title claims abstract description 58
- 208000000689 peptic esophagitis Diseases 0.000 title claims abstract description 49
- 230000007812 deficiency Effects 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims description 8
- 239000002994 raw material Substances 0.000 claims abstract description 20
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 18
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 16
- 241001522129 Pinellia Species 0.000 claims abstract description 16
- 244000197580 Poria cocos Species 0.000 claims abstract description 16
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 16
- 244000183685 Citrus aurantium Species 0.000 claims abstract description 15
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 15
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 15
- 241000132446 Inula Species 0.000 claims abstract description 15
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 15
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 15
- 244000126002 Ziziphus vulgaris Species 0.000 claims abstract description 15
- 235000008397 ginger Nutrition 0.000 claims abstract description 15
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 15
- 235000007716 Citrus aurantium Nutrition 0.000 claims abstract description 14
- 235000005300 cardamomo Nutrition 0.000 claims abstract description 14
- 241000132012 Atractylodes Species 0.000 claims abstract description 13
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 13
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 13
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 13
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 13
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 13
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 13
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 13
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 13
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 13
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 13
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 6
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 5
- 240000002943 Elettaria cardamomum Species 0.000 claims abstract 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 241000245665 Taraxacum Species 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 15
- 238000009835 boiling Methods 0.000 claims description 9
- 241000007126 Codonopsis pilosula Species 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 241000756943 Codonopsis Species 0.000 claims description 6
- 235000013399 edible fruits Nutrition 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 abstract description 23
- 206010067171 Regurgitation Diseases 0.000 abstract description 19
- 239000002253 acid Substances 0.000 abstract description 19
- 230000002441 reversible effect Effects 0.000 abstract description 11
- 201000006549 dyspepsia Diseases 0.000 abstract description 6
- 206010000087 Abdominal pain upper Diseases 0.000 abstract description 5
- 208000024798 heartburn Diseases 0.000 abstract description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract description 2
- 201000004101 esophageal cancer Diseases 0.000 abstract description 2
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 71
- 210000002784 stomach Anatomy 0.000 description 56
- 230000000694 effects Effects 0.000 description 49
- 210000000952 spleen Anatomy 0.000 description 41
- 206010062717 Increased upper airway secretion Diseases 0.000 description 34
- 210000004369 blood Anatomy 0.000 description 34
- 239000008280 blood Substances 0.000 description 34
- 208000026435 phlegm Diseases 0.000 description 34
- 229940079593 drug Drugs 0.000 description 28
- 241000700159 Rattus Species 0.000 description 22
- 230000001737 promoting effect Effects 0.000 description 22
- 201000010099 disease Diseases 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 206010047700 Vomiting Diseases 0.000 description 18
- 210000004877 mucosa Anatomy 0.000 description 17
- 230000000144 pharmacologic effect Effects 0.000 description 17
- 230000008673 vomiting Effects 0.000 description 16
- 230000002411 adverse Effects 0.000 description 15
- 230000002496 gastric effect Effects 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 13
- 235000013305 food Nutrition 0.000 description 12
- 230000001575 pathological effect Effects 0.000 description 12
- 241000234314 Zingiber Species 0.000 description 11
- 210000000038 chest Anatomy 0.000 description 11
- 206010012735 Diarrhoea Diseases 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 241001127714 Amomum Species 0.000 description 9
- 206010011224 Cough Diseases 0.000 description 9
- 210000003238 esophagus Anatomy 0.000 description 9
- 241001092040 Crataegus Species 0.000 description 8
- 210000001015 abdomen Anatomy 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 7
- 208000019505 Deglutition disease Diseases 0.000 description 7
- 101800002372 Motilin Proteins 0.000 description 7
- 102400001357 Motilin Human genes 0.000 description 7
- 230000036528 appetite Effects 0.000 description 7
- 235000019789 appetite Nutrition 0.000 description 7
- 210000000981 epithelium Anatomy 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 210000004400 mucous membrane Anatomy 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 206010000060 Abdominal distension Diseases 0.000 description 6
- 102400000921 Gastrin Human genes 0.000 description 6
- 108010052343 Gastrins Proteins 0.000 description 6
- 206010033557 Palpitations Diseases 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 230000027939 micturition Effects 0.000 description 6
- 210000002445 nipple Anatomy 0.000 description 6
- 238000010792 warming Methods 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 210000000232 gallbladder Anatomy 0.000 description 5
- 210000001156 gastric mucosa Anatomy 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 206010027514 Metrorrhagia Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 208000019790 abdominal distention Diseases 0.000 description 4
- 210000000270 basal cell Anatomy 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000036461 convulsion Effects 0.000 description 4
- 238000002575 gastroscopy Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 239000002023 wood Substances 0.000 description 4
- 241000180579 Arca Species 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- 206010013954 Dysphoria Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 208000031361 Hiccup Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000253121 Inula britannica Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010000210 abortion Diseases 0.000 description 3
- 231100000176 abortion Toxicity 0.000 description 3
- 229940069428 antacid Drugs 0.000 description 3
- 239000003159 antacid agent Substances 0.000 description 3
- 230000001458 anti-acid effect Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000002183 duodenal effect Effects 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 235000003642 hunger Nutrition 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 210000001187 pylorus Anatomy 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000004576 sand Substances 0.000 description 3
- 238000009958 sewing Methods 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 244000141331 Amomum villosum Species 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 2
- 241000092665 Atractylodes macrocephala Species 0.000 description 2
- 208000001387 Causalgia Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 2
- 241000657480 Crataegus pinnatifida Species 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010015137 Eructation Diseases 0.000 description 2
- 206010016807 Fluid retention Diseases 0.000 description 2
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 2
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 208000036626 Mental retardation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028748 Nasal obstruction Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 235000006751 Platycodon Nutrition 0.000 description 2
- 244000274050 Platycodon grandiflorum Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010038084 Rectocele Diseases 0.000 description 2
- 241000238371 Sepiidae Species 0.000 description 2
- 208000032023 Signs and Symptoms Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 241000234299 Zingiberaceae Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 208000017561 flaccidity Diseases 0.000 description 2
- 239000010135 fructus aurantii immaturus Substances 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 230000030135 gastric motility Effects 0.000 description 2
- 230000005176 gastrointestinal motility Effects 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000015994 miscarriage Diseases 0.000 description 2
- 229960000381 omeprazole Drugs 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 229930189914 platycodon Natural products 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 208000000995 spontaneous abortion Diseases 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- ZGDLVKWIZHHWIR-UHFFFAOYSA-N 4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]morpholine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N2CCOCC2)N=C1 ZGDLVKWIZHHWIR-UHFFFAOYSA-N 0.000 description 1
- YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 235000006480 Acorus calamus Nutrition 0.000 description 1
- 244000205574 Acorus calamus Species 0.000 description 1
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 244000059800 Amomum compactum Species 0.000 description 1
- 241001573260 Amomum krervanh Species 0.000 description 1
- 241001571352 Amomum longiligulare Species 0.000 description 1
- 241000628923 Anadara sativa Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000209524 Araceae Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 208000023665 Barrett oesophagus Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 240000002319 Citrus sinensis Species 0.000 description 1
- 241000357628 Codonopsis pilosula subsp. tangshen Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 235000017159 Crataegus pinnatifida Nutrition 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000007217 Esophageal Stenosis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018045 Gastroptosis Diseases 0.000 description 1
- 208000018779 Globus Sensation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 241000825107 Hierochloe Species 0.000 description 1
- 235000015466 Hierochloe odorata Nutrition 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 description 1
- 206010030194 Oesophageal stenosis Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241001522232 Pinellia ternata Species 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 241001441745 Sepia esculenta Species 0.000 description 1
- 241001663378 Sepiella maindroni Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 235000015055 Talinum crassifolium Nutrition 0.000 description 1
- 241000292546 Taraxacum mongolicum Species 0.000 description 1
- 241000224239 Tegillarca granosa Species 0.000 description 1
- 240000004429 Tephrosia purpurea Species 0.000 description 1
- 235000017517 Tephrosia purpurea Nutrition 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 235000006545 Ziziphus mauritiana Nutrition 0.000 description 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- UJOHNXQDVUADCG-UHFFFAOYSA-L aluminum;magnesium;carbonate Chemical compound [Mg+2].[Al+3].[O-]C([O-])=O UJOHNXQDVUADCG-UHFFFAOYSA-L 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- ITMSAWKLJVGBIT-UHFFFAOYSA-N carbocloral Chemical compound CCOC(=O)NC(O)C(Cl)(Cl)Cl ITMSAWKLJVGBIT-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- -1 dehydrated Substances 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical group C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 208000028653 esophageal adenocarcinoma Diseases 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 210000003236 esophagogastric junction Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- 235000002780 gingerol Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910052595 hematite Inorganic materials 0.000 description 1
- 239000011019 hematite Substances 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- LIKBJVNGSGBSGK-UHFFFAOYSA-N iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Fe+3].[Fe+3] LIKBJVNGSGBSGK-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000011133 lead Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000027905 limb weakness Diseases 0.000 description 1
- 231100000861 limb weakness Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000000111 lower esophageal sphincter Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960004085 mosapride Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 229910052592 oxide mineral Inorganic materials 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229960001778 rabeprazole sodium Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007464 sphincterotomy Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗中虚气逆型反流性食管炎的组合物,其特征在于,由重量份数的原材料制成:旋复花80~120份,党参120~160份,生姜20~50份,赭石120~160份,半夏100~150份,白术100~150份,枳实100~150份,茯苓120~160份,山楂120~160份,蒲公英100~150份,大枣100~150份,炙甘草80~120份,砂仁80~100份,豆蔻80~100份,瓦楞子120~160份,海螵蛸120~160份。本发明提供的组合物,可用于治疗中虚气逆型反流性食管炎引起的烧心、吐酸、反酸、胃脘痛、胸痹等症状,并降低患者食管癌等并发症的发病率。
Description
技术领域
本发明涉及中药组合物领域,具体为一种治疗中虚气逆型反流性食管炎组合物及其制备方法。
背景技术
反流性食管炎(reflux esophagitis,RE)是指由各种原因导致,食管受到反流的胃与十二指肠内容物损害,而发生的一种以食管黏膜破损为特征的一种炎症性疾病。反流性食管炎病灶以食管中下段为主,60-70岁人群发病率最高。典型症状为进食后60min内胸骨后方的灼烧感,伴从上腹部向颈部放射性疼痛,以及喉咙或口腔中有酸味或灼烧液体,30%患者可能出现吞咽困难。常见的并发症为食管狭窄、出血、Barrett食管及食管腺癌等。RE是胃食管反流病(gastroesophageal reflux disease,GERD)的一种,约占GERD的30%~40%。根据流行病学调查,我国胃食管反流病发病率为5.77%,反流性食管炎发病率为1.92%。反流性食管炎目前在我国的发病率呈现逐年增长的趋势。
西医目前没有针对反流性食管炎治疗的药物,主要以抑酸抑酶及促胃动力的药物进行对症治疗,常见药物有奥美拉唑等抑酸药物,以及促进胃动力、保护胃黏膜如莫沙必利片、铝碳酸镁片等药物。通过临床治疗的长期观察来看此类药物对于患者症状具有短期的缓解作用,但对部分患者疗效并不令人满意,长期使用这些药容易造成萎缩性胃炎,并且患者常出现病情反复以及频发的药物不良反应,无法解决反流患者的根本问题。而外科手术治疗需要具备相应的手术指征,应用范围有限。
近年来中医药治疗反流性食管炎积累了丰富的经验,已证实有良好的临床疗效。根据《胃食管反流病中医诊疗共识意见(2017)》中医症候分类标准,将反流性食管炎分为以下六种类型:肝胃郁热证、胆热犯胃证、气郁痰阻证、瘀血阻络证、中虚气逆证和脾虚湿热证。反流性食管炎可归属于中医食管瘅、吐酸、嘈杂、反胃、痞满、胸痹、噎膈等疾病范畴。根据该病病位在食管,与胃密切相关。若生活不规律,饮食不节,嗜食肥甘厚味,夏天贪食饮冷,这些都会导致脾胃虚弱,脾胃纳腐熟的功能受损,不能正常调节气机,胃失和降,则可出现吞酸、吐酸等症。
中医在辨证论治理论支持下进行治疗,其疗效显著,副作用少,复发率低,充分体现了中医整体治疗的特色与优势。中医治疗反流性食管炎以“和法”为主,或和中消导、或疏肝和胃、或补益脾胃、或辛开苦降,在改善症状、减轻炎症、促进受损食管黏膜修复及增加胃动力等方面,取得了良好的疗效。
发明内容
为了解决上述技术问题,本发明提供了一种治疗中虚气逆型反流性食管炎的组合物,本发明还提供了治疗中虚气逆型反流性食管炎的组合物的制备方法。用于治疗中虚气逆型反流性食管炎引起的烧心、吐酸、反酸、胃脘痛、胸痹等症状,并降低患者食管癌等并发症的发病率。
为实现以上第一目的,本发明通过以下技术方案予以实现:一种治疗中虚气逆型反流性食管炎的组合物,其特征在于,由以下重量份数的原材料制成:旋复花80~120份,党参120~160份,生姜20~50份,赭石120~160份,半夏100~150份,白术100~150份,枳实100~150份,茯苓120~160份,山楂120~160份,蒲公英100~150份,大枣100~150份,炙甘草80~120份,砂仁80~100份,豆蔻80~100份,瓦楞子120~160份,海螵蛸120~160份。
作为优选:由以下重量份数的原材料制成:旋复花100份,党参150份,生姜30份,赭石150份,半夏120份,白术120份,枳实120份,茯苓150份,山楂150份,蒲公英120份,大枣120份,炙甘草100份,砂仁90份,豆蔻90份,瓦楞子150份,海螵蛸150份。
作为优选:由以下重量份数的原材料制成:旋复花120份,党参160份,生姜50份,赭石120份,半夏100份,白术150份,枳实150份,茯苓160份,山楂160份,蒲公英100份,大枣150份,炙甘草120份,砂仁100份,豆蔻100份,瓦楞子160份,海螵蛸160份。
作为优选:由以下重量份数的原材料制成:旋复花80份,党参120份,生姜20份,赭石160份,半夏150份,白术100份,枳实100份,茯苓120份,山楂120份,蒲公英150份,大枣100份,炙甘草80份,砂仁80份,豆蔻90份,瓦楞子140份,海螵蛸120份。
本发明的第二目的是这样实现的:一种治疗中虚气逆型反流性食管炎的组合物的制备方法,其特征在于:将上述原料药物加水600-800份,在18-25℃下,浸泡15-25min,然后武火烧开,再转文火,煎煮20-30min,过滤,得滤液,备用;滤渣加水300-400份,武火烧开后,转文火,煎煮10-15min,过滤,弃去滤渣,得滤液,合并两次滤液,浓缩至两次加水量的1/3,即得。
本发明原料价廉易得,制备方法简单,成本低,易服用,效果好,能明显缓解患者症状,加快食管黏膜组织修复,是治疗中虚气逆型反流性食管炎药物上的创新。
本发明的用于治疗中虚气逆型反流性食管炎的中药组合药物的16味原料药中单味药的功效、主治病症、医籍记载及药理作用如下:
本发明中所述的旋复花为菊科植物旋复花Inula japonica Thunb.或欧亚旋复花的I.britannica L.的头状花序,具有降气行水化痰,降逆止呕的作用,主治胸中痰结,胁下胀满,咳喘,呃逆,唾如胶漆,心下痞鞕,噫气不除,大腹水肿。《本经》中:“主结气,胁下满,惊悸。除水,去五脏间寒热,补中,下气。”《药性论》中:“主肋胁气,下寒热水肿,主治膀胱宿水,去逐大腹,开胃,止呕逆不下食。”现代药理学研究表明旋覆花含三萜类皂苷、鞣质、蜡醇、豆甾醇等多种甾醇。具有祛痰、抑菌、刺激胃肠粘膜等作用。
本发明中所述的党参为桔梗科党参属植物党参Codonopsis pilosula(Franch.)Nannf.素花党参C.Pilosula Nannf.var.Modesta(Nannf.)L.T.Shen或川党参C.tangshenOliv.的根,具有补中益气,和胃生津,祛痰止咳的作用,主治脾虚食少便溏,四肢无力,心悸,气短,口干,自汗,脱肛,阴挺。党参最早记录于《本草从新》,认为其具有补脾益肺、养血生津的功效。现代药理学研究表明党参中含有黄酮类、生物碱类、糖类、皂苷类、甾体类、氨基酸类等活性成分。具有提高机体免疫力、调节改善消化系统、抗炎、调节内分泌系统、改善造血功能、预防动脉血管粥样硬化和高血压以及抗衰老的作用。
本发明中所述的生姜为姜科植物姜Zingiber officinale Roscoe的新鲜根茎,具有解表散寒,温中止呕,温肺止咳的作用,用于除风邪寒热,伤寒头痛鼻塞,咳逆上气,止呕吐,去痰下气等。《本经》中:“久服去臭气,通神明。”《名医别录》中:“味辛,微温。主治伤寒头痛、鼻塞、咳逆上气,止呕吐。又,生姜,微温,辛,归五藏。去痰,下气,止呕吐,除风邪寒热。久服小志少智,伤心气。”现代药理学研究表明生姜含有挥发油和姜辣素等多种成分。具有保护胃黏膜细胞、抑制盐酸性和应激性胃黏膜损伤、抑制胃机能及直接兴奋胃平滑肌、末梢性镇吐等作用。
本发明中所述的赭石为氧化物类矿物赤铁矿Haematitum的矿石,具有平肝镇逆,凉血止血的作用,用于噫气呕逆,噎膈反胃,哮喘,惊痫,吐血,鼻衄,肠风,痔瘘,崩漏带下等。《本经》中:“主贼风蛊毒,腹中毒邪气,女子赤沃漏下。”《名医别录》中:“主带下百病,产难,胞衣不出,堕胎,养血气,除五脏血脉中热,血痹,血瘀,大人小儿惊气入腹,及阴痿不起。”《药性论》中:“治女子崩中淋沥不止,疗生子不落。”现代药理学研究表明赭石主含三氧化二铁(Fe2O3),其中铁70%,氧30%,并含有硅、铝、钛、镁、锰、钙、铅、砷等杂质。具有兴奋肠管、促进肠蠕动、促进红细胞及血红蛋白的新生及中枢镇静等作用。
本发明中所述的半夏为天南星科植物半夏Pinellia ternata(Thunb.)Breit.的块茎,具有燥湿化痰,降逆止呕,消痞散结的作用,用于痰多咳喘,痰饮眩悸,风痰眩晕,痰厥头痛,呕吐反胃,胸脘痞闷,梅核气;生用外治痈肿痰核等。《本经》中:“主贼风蛊毒,腹中毒邪气,女子赤沃漏下。”《名医别录》中:“主带下百病,产难,胞衣不出,堕胎,养血气,除五脏血脉中热,血痹,血瘀,大人小儿惊气入腹,及阴痿不起。”《药性论》中:“治女子崩中淋沥不止,疗生子不落。”现代药理学研究表明半夏含有挥发油、麻黄碱类、皂苷等成分。具有镇咳、祛痰、镇吐、催吐、抗溃疡及抗肿瘤作用等作用。
本发明中所述的白术为菊科植物Atractylodes macrocephala Koidz的根茎,具有健脾益气,燥湿利水,止汗,安胎的功效,用于脾虚食少,腹胀泄泻,痰饮眩悸,水肿,自汗,胎动不安。《医学启源》记载:“除湿益燥,和中益气,温中,去脾胃中湿,除胃热,强脾胃,进饮食,安胎。”《药品化义》中:“凡郁结气滞,胀闷积聚,吼喘壅塞,胃痛由火,痈疽多脓,黑瘦人气实作胀,皆宜忌用。”现代药理学研究表明白术具有利尿、降血糖、提高抗病能力、抗凝血、抗肿瘤等作用。
本发明中所述的枳实为芸香科植物酸橙Citrus aurantium L.及栽培变种或甜橙Citrus sinensis Osbeck的干燥幼果,具有破气消积,化痰散痞的功效,用于积滞内停,痞满胀痛,大便秘结,泻痢后重,结胸,胃下垂,子宫脱垂,脱肛。《药品化义》:“枳实专泄胃实,开导坚结,故主中脘以治血分,疗脐腹间实满,消痰癖、祛停水、逐宿食、破结胸、通便闭、非此不能也。若皮肤作痒,因积血滞于中,不能营养肌表,若饮食不思,因脾郁结不能运化,皆取其辛散苦泻之力也。为血分中之气药,惟此称最。”现代药理学研究表明枳实具有升压、改善微循环、调节胃肠道运动、增强心肌收缩力等作用。
本发明中所述的茯苓为多孔菌科真菌茯苓Poria cocos(Schw)Wolf的菌核,具有渗湿利水,益脾胃保肾,安神生津等功效,用于止渴,利小便,除湿益燥,和中益气。《本经》中:“胸胁逆气,忧恚惊邪恐悸,心下结痛,寒热烦满咳逆,口焦舌干,利小便。久服,安魂养神,不饥延年。”现代药理学研究表明茯苓具有调节免疫、利尿、化石保肝、抗白血病、抗肿瘤、抗疲劳、抗衰老等作用。
本发明中所述的山楂为蔷薇科植物山里红Crataegus pinnatifidaBge.var.major N.E.Br.或山楂Crataegus pinnatifida Bge.的成熟果实,具有健脾开胃、消食化滞、活血化痰等功效,用于胸膈脾满、疝气、血淤、闭经等。《本草纲目》中:“化饮食,消肉积症瘕,痰饮痞满吞酸,滞血痛胀。”现代药理学研究表明茯苓具有降血脂、血压、强心、抗心律不齐等作用。
本发明中所述的蒲公英为菊科植物蒲公英Taraxacum mongolicum Hand.-Mazz.碱地蒲公英Taraxacum borealisinense Kitam.或同属数种植物的全草,具有利尿、缓泻、退黄疸、利胆等功效,用于清热解毒、消肿散结、利尿通淋等。现代药理学研究表明蒲公英可以用于淋巴腺炎,瘰疬,疔毒疮肿,急性结膜炎,感冒发热,急性扁桃体炎,急性支气管炎,胃炎,肝炎,胆囊炎,尿路感染等的治疗。
本发明中所述的大枣为鼠李科植物枣Ziziphus jujuba Mill.的成熟果实,具有补中益气、养血安神等功效,用于脾气虚证、脏躁失眠等。《本经》中:“主心腹邪气,安中养脾,助十二经。平胃气,通九窍,补少气、少津液,身中不足,大惊,四肢重,和百药。”现代药理学研究表明大枣能够增强肌力、消除疲劳、扩张血管、增加心肌收缩力、改善心肌营养,对防治心血管系统疾病有良好的作用。
本发明中所述的炙甘草为甘草的炮制品。甘草为豆科植物甘草Glycyrrhizauralensis Fisch.、胀果甘草Glycyrrhiza inflata Bat.或光果甘草GlycyrrhizaglabraL.的干燥根和根茎。甘草别名为国老、甜草、乌拉尔甘草、甜根子,是一种补益类中草药。甘草为多年生草本植物甘草的根及根茎,它的作用颇为广泛,性味甘平,归心、肺、脾、胃经。在中药汤剂及中成药配伍中,常用于补气益脾、和中缓急、调和诸药之功效。其生者偏于清热,炙者则偏于补中。蜜炙主治脾胃功能减退,大便溏薄,乏力发热以及咳嗽、心悸等。甘草有类似肾上腺皮质激素样作用,对组胺引起的胃酸分泌过多有抑制作用,并有抗酸和缓解胃肠平滑肌痉挛作用,能够抑制长期胃酸导致的胃溃疡。
本发明中所述的砂仁为姜科植物阳春砂Amomum villosum Lour.、绿壳砂Amomumvillosum Lour.Var.Xanthioides T.L.Wu et Senjen或海南砂Amomum longiligulareT.L.Wu的成熟果实,具有化湿开胃、温脾止泻、理气安胎等功效,主治脾胃气滞,宿食不消,腹痛痞胀,噎膈呕吐,寒泻冷痢等。现代药理学研究表明砂仁能够调节胃肠功能、抗炎、镇痛、抗血小板聚集、降糖等作用。
本发明中所述的豆蔻为姜科植物白豆蔻Amomum kravanh Pierre ex Gagnep.或爪哇白豆蔻Amomum compactum Soland ex Moton.的干燥成熟果实,具有化湿消痞,行气温中,开胃消食等功效,用于湿浊中阻,不思饮食,湿温初起,胸闷不饥,寒湿呕逆,胸腹胀痛,食积不消等。《别录》中:“温中,心腹痛,呕吐,去口臭气。”《本草纲目》中:“治瘴疠寒疟,伤暑吐下泄痢,噎膈反胃,痞满吐酸,痰饮积聚,妇人恶阻带下,除寒燥湿,开郁破气,杀鱼肉毒。”现代药理学研究表明豆蔻能够促进胃液分泌、增进胃肠蠕动、祛除胃肠积气、芳香健胃及止吐等作用。
本发明中所述的瓦楞子为蚶科动物魁蚶Arca inflata Reeve、泥蚶Arca granosaLinnaeus及毛蚶Arca subcrenata Lischke的贝壳,具有消痰化瘀,软坚散结,制酸止痛等功效,用于顽痰积结,粘稠难咯,瘿瘤,瘰疬,瘕痞块,胃痛泛酸等。《本经》中:“与鳖甲、虻虫,同为消疟母之味。”《本草用法研究》:“同广木香、绿萼梅、路路通,治胃院痰积,气滞胀痛。”现代药理学研究表明瓦楞子能够治疗胃及十二指肠溃疡。
本发明中所述的海螵蛸为乌贼科动物无针乌贼Sepiella maindroni deRoehebrune或金乌贼Sepia esculenta Hoyle的干燥内壳,具有收敛止血,涩精止带,制酸止痛,收湿敛疮等功效,用于吐血衄血,崩漏便血,遗精滑精,赤白带下,胃痛吞酸;外治损伤出血,湿疹湿疮,溃疡不敛等。《本经》中:“味咸,微温。”《药性论》:“有小毒。”现代药理学研究表明海螵蛸能够中和胃酸、保护黏膜、抗溃疡、促进成骨、抗放射等作用。
反流性食管炎可归属于中医食管瘅、吐酸、嘈杂、反胃、痞满、胸痹、噎膈等疾病范畴。该病病位在食管,与胃密切相关。胃失和降,胃气上逆为反流性食管炎的基本病机,肝胆失于疏泄、脾失健运、胃失和降、肺失宣肃、胃气上逆,上犯食管,形成本病的一系列临床症状。禀赋不足、脾胃虚弱为胃食管反流病发病基础。病程日久,气病及血,则因虚致瘀或气滞血瘀。若生活不规律,饮食不节,嗜食肥甘厚味,夏天贪食饮冷,这些都会导致脾胃虚弱,脾胃纳腐熟的功能受损,不能正常调节气机,胃失和降,则可出现吞酸、吐酸等症。从而导致食管受到反流的胃与十二指肠内容物损害,而发生食管黏膜破损及一系列并发症。
本病病理因素有虚实两端:属实的病理因素:痰、热、湿、郁、气、瘀;属虚者责之于脾。本病病机特点:一为逆,二为热,三为郁。胃失和降,胃气上逆为反流性食管炎的基本病机,肝胆失于疏泄、脾失健运、胃失和降、肺失宣肃、胃气上逆,上犯食管,形成本病的一系列临床症状。禀赋不足、脾胃虚弱为反流性食管炎发病基础,土虚木乘或木郁土壅,致木气恣横无制,肝木乘克脾土,胆木逆克胃土,导致肝胃、肝脾或胆胃不和;气郁日久,化火生酸,肝胆邪热犯及脾胃,脾气当升不升,胃气当降不降,肝不随脾升,胆不随胃降,以致胃气挟火热上逆;肝火上炎侮肺,克伐肺金,消灼津液,肺失肃降而咳逆上气,气机不利,痰气郁阻胸膈;病程日久,气病及血,则因虚致瘀或气滞血瘀。
反流性食管炎的中医治疗根据证型辨证施治。临证治疗以畅达气机为要,依病情分别施以疏肝泄热、和胃降逆、理气化痰、活血祛瘀、健脾化湿;兼见虚证,辨明气血阴阳,补而不滞。中虚气逆型反流性食管炎在治法上以疏肝理气,健脾和胃为原则。本发明中的方中旋覆花苦辛咸温,性主降,善于下气消痰,降逆止噫,赭石重坠降逆以止呃,下气消痰,为君药。半夏祛痰散结,降逆和胃;砂仁、豆蔻有化湿开胃,温脾止呕;生姜和胃降逆增其止呕之力,并可宣散水气以助祛痰之功为臣药;党参、白术、茯苓、大枣、炙甘草甘温益气,健脾养胃,以治中虚气弱之本;枳实、山楂消积行气,瓦楞子、海螵蛸消痰化瘀、制酸止痛;蒲公英补脾和胃,泻火,治噎膈,为佐药。炙甘草调和药性,兼作使药。诸药相合,标本兼治,共奏降逆化痰、益气和胃,使逆气得降,痰浊得消,中虚得复。
药理实验表明,本发明的组合物具有良好的抗炎、治疗黏膜糜烂作用,能有效治疗中虚气逆型反流性食管炎,并且毒性小,用药安全。
本发明中各药味优势互补,诸药合用,充分发挥了各味药之间的协同作用,使本品多种活性成分共同作用,通过多种途径达到治疗中虚气逆型反流性食管炎的目的。
具体实施方式
下面结合实施例对本发明做进一步描述。
实施例1
由以下重量计的原料药物制成:旋复花100份,党参150份,生姜30份,赭石150份,半夏120份,白术120份,枳实120份,茯苓150份,山楂150份,蒲公英120份,大枣120份,炙甘草100份,砂仁90份,豆蔻90份,瓦楞子150份,海螵蛸150份制成,其中,将上述原料药物加水600-800ml,在18-25℃下,浸泡15-25min,然后武火烧开,再转文火,煎煮20-30min,过滤,得滤液,备用;滤渣加水300-400ml,武火烧开后,转文火,煎煮10-15min,过滤,弃去滤渣,得滤液,合并两次滤液,浓缩至两次加水量的1/3,即得。
实施例2
由以下重量计的原料药物制成:旋复花120份,党参160份,生姜50份,赭石120份,半夏100份,白术150份,枳实150份,茯苓160份,山楂160份,蒲公英100份,大枣150份,炙甘草120份,砂仁100份,豆蔻100份,瓦楞子160份,海螵蛸160份。其中,将上述原料药物加水600-800ml,在18-25℃下,浸泡15-25min,然后武火烧开,再转文火,煎煮20-30min,过滤,得滤液,备用;滤渣加水300-400ml,武火烧开后,转文火,煎煮10-15min,过滤,弃去滤渣,得滤液,合并两次滤液,浓缩至两次加水量的1/3,即得。
实施例3
由以下重量计的原料药物制成:旋复花80份,党参120份,生姜20份,赭石160份,半夏150份,白术100份,枳实100份,茯苓120份,山楂120份,蒲公英150份,大枣100份,炙甘草80份,砂仁80份,豆蔻90份,瓦楞子140份,海螵蛸120份。其中,将上述原料药物加水600-800ml,在18-25℃下,浸泡15-25min,然后武火烧开,再转文火,煎煮20-30min,过滤,得滤液,备用;滤渣加水300-400ml,武火烧开后,转文火,煎煮10-15min,过滤,弃去滤渣,得滤液,合并两次滤液,浓缩至两次加水量的1/3,即得。
上述药物的有效组合,互相支持,并经科学制备,具有降逆化痰、益气和胃之功效。
实施例4
组合物在大鼠中虚气逆型反流性食管炎模型中的药效学研究
1、大鼠反流性食管炎模型制备
大鼠均于术前24h禁食不禁水,应用10%水合氯醛腹腔注射(0.3mL/100g)进行麻醉,严格按照无菌操作,行不全幽门结扎+食管下括约肌切开术。具体操作如下:大鼠正中腹切口,用外径为1.5mm的金属针由胃体部位穿刺入胃并通过幽门至十二指肠端,避开血管,缝扎金属针外部剩余幽门,缝扎完毕后,将金属针抽出,由此来保证大鼠在模型建立后所剩余的幽门内径均匀一致,缝合胃部穿刺点,之后于食管-胃交界处纵行切开食管下括约肌约0.5cm,分离至黏膜层完全暴露于视野中。
2、分组及给药
SD雄性大鼠60只(体重200±10g)随机分成假手术组、模型组、西药组、实施例1组、实施例2组和实施例3组,每组各10只。造模第2天,实施例1组给予本发明实施例1所述中药组合物1g/kg,实施例2组给予本发明实施例2所述中药组合物1g/kg,实施例3组给予本发明实施例3所述中药组合物1g/kg,模型组给予等体积生理盐水,西药组以3mg/kg剂量给予奥美拉唑,每天分2次灌胃。给药治疗7d,记录大鼠体质量变化,第8天处理各组大鼠,观察反流性食管炎病理分级,取血液以及食管标本,进行相关研究。
3、标本的采集和处理
病理学切片:末次给药后24h处理动物,禁食不禁水;取食管下段组织(自胃食管交界上0.5cm处向咽喉部截取1cm长食管),置入10%甲醛溶液中,脱水,石蜡包埋,切片,苏木精-伊红染色,树脂封片。
血清胃动素(MTL)水平及胃泌素(GAS)水平测定:腹主动脉取血2mL,注入含7.5%EDTA二钠30μL和抑肽酶40μL的试管中,混匀,4℃3000r/min离心10min,取血浆,置-20℃保存待测胃动素;另腹主动脉取血2mL注入非抗凝试管,置于室温,3000r/min离心10min,取血清,-20℃保存待测胃泌素。采用放射免疫分析法严格按照试剂盒说明的操作程序测定。
4、实验指标的检测和观察指标
一般状态:观察大鼠的精神状态、活动情况、毛发光泽度、食欲、大便性状、死亡等,造模前后及处死前分别称体质量并记录;实验第1、7、14、20天各称体重1次。
食管黏膜肉眼表现及病理形态学观察:分别处死动物并取食管下段,应用生理盐水轻冲洗食管腔,观察肉眼大体表现并进行RE分级(肉眼表现及病理分级均采用反流性食管炎诊断及治疗指南(2003年)),并进行打分。
取大鼠食管下段,HE染色后,在光镜下观察鳞状上皮厚度、乳头厚度、中性粒细胞浸润程度等病理指标。
5、实验指标的检测和观察标准
食管黏膜的肉眼表现及病理形态学观察方法
肉眼表现为取材后直接用肉眼观察所见:病理形态学用光镜观察。食管黏膜的肉眼表现及病理形态学观察标准均采用反流性食管炎诊断及治疗指南(2003年),见表1。
表1食管黏膜的肉眼表现积分
注:0级为正常,Ia级为轻度RE,Ib级为轻度RE,II级为中度RE,III级为重度RE。
表2反流性食管炎病理分级
6、结果
各项指标检测结果
一般状态:经过造模后的各组大鼠均有不同程度的活动欠敏捷,动作迟缓,被毛疏松,光泽减弱、晦黯,腹胀,体重停滞不增,甚或减轻。假手术组恢复最快,实施例组在给予治疗后,上述症状、体征逐渐好转,恢复速度要快于西药组,最终各个实施例组、西药组大鼠均恢复趋于正常,模型组恢复最差。
食管黏膜肉眼表现:正常大鼠食管黏膜完整,光滑,呈白色,经过造模手术后的大鼠黏膜均有不同程度的发红,呈点状或条状,甚或出现糜烂,最为严重者有溃疡形成。如表3所示:
表3各组大鼠治疗14天后食管黏膜肉眼表现分级情况(%)
以上结果表明:治疗14天后,各实施例组的RE分级优于西药组和模型组。
食管黏膜病理形态学观察:正常大鼠黏膜除上皮细胞层内间或存在少量炎细胞外,无其他异常表现,经过造模手术的大鼠黏膜可根据病情的不同而上皮细胞层内出现炎性细胞浸润,鳞状上皮增生,黏膜固有层乳头延伸,成纤维细胞增多,严重者出现黏膜糜烂、溃疡形成。如表4所示:
表4各组大鼠治疗14天后食管黏膜病理分级情况(%)
以上结果表明:治疗14天后,各实施例组的食管黏膜病理分级优于西药组和模型组。
在光镜下观察鳞状上皮厚度、乳头厚度、基底细胞层数。参考Seefeld的方法进行测量,结果见表5。
表5反流性食管炎大鼠食管上皮测量结构(x±s)
组别 | 鳞状上皮厚度 | 乳头厚度 | 基底细胞层数 |
假手术组 | 19.48±0.35 | 23.18±4.26 | 1.67±0.34 |
模型组 | 36.44±3.46 | 85.63±5.46 | 4.84±0.52 |
西药组 | 27.78±3.86 | 31.64±6.53 | 2.39±0.46 |
实施例1组 | 18.37±2.05 | 24.42±4.17 | 2.18±0.35 |
实施例2组 | 20.64±3.25 | 20.58±6.73 | 2.14±0.62 |
实施例3组 | 21.75±2.66 | 22.46±6.25 | 2.16±0.33 |
鳞状上皮厚度:各实施例组与模型组比较,有极显著性差异(P<0.01);与假手术组比较,无显著差异(P>0.05);与西药组比较有显著性差异(P<0.05)。
乳头厚度:各实施例组与模型组比较,有极显著性差异(P<0.01);与假手术组比较,无显著差异(P>0.05);与西药组比较有显著性差异(P<0.05)。
基底细胞层数:各实施例组与模型组比较,有极显著性差异(P<0.01);与假手术组比较,有显著性差异(P<0.05);与西药组比较无显著性差异(P>0.05)。
以上结果表明:各实施例组对反流性食管炎大鼠的鳞状上皮厚度、黏膜固有层乳头厚度和基底细胞层数有明显的改善作用,能有效的治疗大鼠反流性食管炎,且其疗效优于西药组。
血浆MTL水平及血清GAS水平测定:采用放射免疫分析法严格按照试剂盒说明的操作程序测定。
表6各实施例组对反流性食管炎大鼠血清MTL、GAS的影响
组别 | 血浆胃动素(ng/L) | 血浆胃泌素(ng/L) |
假手术组 | 195.34±14.42 | 205.65±17.84 |
模型组 | 90.25±6.36 | 112.33±12.85 |
西药组 | 192.36±15.77 | 207.64±18.45 |
实施例1组 | 198.65±17.22 | 201.53±14.52 |
实施例2组 | 194.35±16.55 | 203.85±18.64 |
实施例3组 | 189.27±19.66 | 206.35±15.38 |
表6结果显示,各实施例组与模型组比较,有显著性差异(P<0.05);与假手术组比较,无显著差异(P>0.05);与西药组比较无显著性差异(P>0.05)。
以上结果表明:各实施例组能够明显提高食管炎模型大鼠血清MTL、GASL水平,对反流性食管炎模型大鼠有良好的治疗作用。
实施例5
中虚气逆型反流性食管炎患者有效性研究
80例中虚气逆型反流性食管炎的患者,男女不限,年龄20~52岁,病程5个月~4年,随机分为4组,20人/组;另选取肝胃郁热型和脾虚湿热型患者各40例,年龄24~55岁,病程6个月~4年,分别随机分为4组,10人/组(上述所有女性病例无妊娠期及哺乳期患者)。
西医诊断标准
参考《中国胃食管反流病专家共识意见(2014)》中的相关诊断标准。
中医诊断标准
参考《胃食管反流病中医诊疗共识意见(2017)》中医症候分类标准。
中虚气逆证:主症反酸或泛吐清水,嗳气或反流;次症胃脘隐痛,胃痞胀满,食欲不振,神疲乏力,大便溏薄;舌脉舌淡,苔薄;脉细弱。
肝胃郁热证:主症烧心,反酸,次症胸骨后灼痛,胃脘灼痛,脘腹胀满,嗳气或反食,易怒,易饥;舌脉舌红,苔黄,脉弦。
脾虚湿热证:主症餐后反酸,饱胀;次症胃脘灼痛,胸闷不舒,不欲饮食,身倦乏力,大便溏滞;舌脉舌淡或红,苔薄黄腻,脉细滑数。
治疗方法
中药治疗组:共120人,分别用本发明实施例1-3所述的中药组合物,每日1剂,水煎取汁300mL,分3次服。均以4周为一个疗程。
西药治疗对照组:共40人,使用抑酸药和胃肠动力药进行治疗,抑酸药选择雷贝拉唑钠肠溶片(20mg/片)20mg/次,每日2次;胃肠动力药选择多潘立酮片(10mg/片),每日饭前半小时口服,每次10mg,每天3次。以4周为一个疗程。
疗效标准
临床疗效以治愈、显效、有效、无效4个等级评定。治愈:胃镜检查显示胃黏膜正常,且症状、体征(胃灼热、反酸、胸骨后疼痛)消失;显效:胃镜检查显示胃黏膜症状改善,胃镜分级改善大于2级,上述症状、体征轻微;有效:胃镜检查显示胃黏膜症状缓解,胃镜分级改善大于1级,上述症状、体征减轻;无效:病情恶化。总有效率=(治愈+显效+有效)例数/总例数×100%。
结果
表7治疗结果
由以上实施例可以看出,本发明的治疗中虚气逆型反流性食管炎的中药组合物,全方配伍合理,具有降逆化痰、益气和胃,消痰化瘀的作用,经实验证实,本发明所述组合物对其它类型的反流性食管炎基本无效,但是能够从根本上提高对中虚气逆型反流性食管炎的疗效,总有效率达到95%以上,且各实施例组的总有效率明显高于西药对照组。
毒副作用
治疗组和对照组病例治疗前后均未出现明显的不良反应及明显的毒副作用。
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。
Claims (4)
1.一种治疗中虚气逆型反流性食管炎的组合物,其特征在于,由以下重量份数的原材料制成:旋复花80~120份,党参120~160份,生姜20~50份,赭石120~160份,半夏100~150份,白术100~150份,枳实100~150份,茯苓120~160份,山楂120~160份,蒲公英100~150份,大枣100~150份,炙甘草80~120份,砂仁80~100份,豆蔻80~100份,瓦楞子120~160份,海螵蛸120~160份;
制备方法为:将所述原料药物加水600-800份,在18-25℃下,浸泡15-25min,然后武火烧开,再转文火,煎煮20-30min,过滤,得滤液,备用;滤渣加水300-400份,武火烧开后,转文火,煎煮10-15min,过滤,弃去滤渣,得滤液,合并两次滤液,浓缩至两次加水量的1/3,即得。
2.根据权利要求1所述治疗中虚气逆型反流性食管炎的组合物,其特征在于,由以下重量份数的原材料制成:旋复花100份,党参150份,生姜30份,赭石150份,半夏120份,白术120份,枳实120份,茯苓150份,山楂150份,蒲公英120份,大枣120份,炙甘草100份,砂仁90份,豆蔻90份,瓦楞子150份,海螵蛸150份。
3.根据权利要求1所述治疗中虚气逆型反流性食管炎的组合物,其特征在于,由以下重量份数的原材料制成:旋复花120份,党参160份,生姜50份,赭石120份,半夏100份,白术150份,枳实150份,茯苓160份,山楂160份,蒲公英100份,大枣150份,炙甘草120份,砂仁100份,豆蔻100份,瓦楞子160份,海螵蛸160份。
4.根据权利要求1所述治疗中虚气逆型反流性食管炎的组合物,其特征在于,由以下重量份数的原材料制成:旋复花80份,党参120份,生姜20份,赭石160份,半夏150份,白术100份,枳实100份,茯苓120份,山楂120份,蒲公英150份,大枣100份,炙甘草80份,砂仁80份,豆蔻90份,瓦楞子140份,海螵蛸120份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310788417.8A CN116712523B (zh) | 2023-06-30 | 2023-06-30 | 一种治疗中虚气逆型反流性食管炎组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310788417.8A CN116712523B (zh) | 2023-06-30 | 2023-06-30 | 一种治疗中虚气逆型反流性食管炎组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116712523A CN116712523A (zh) | 2023-09-08 |
CN116712523B true CN116712523B (zh) | 2024-04-26 |
Family
ID=87869691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310788417.8A Active CN116712523B (zh) | 2023-06-30 | 2023-06-30 | 一种治疗中虚气逆型反流性食管炎组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116712523B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102580019A (zh) * | 2011-01-14 | 2012-07-18 | 天津市中宝制药有限公司 | 一种治疗反流性食管炎的中药组合物 |
CN102847090A (zh) * | 2011-06-30 | 2013-01-02 | 苏州知微堂生物科技有限公司 | 一种旋复代赭汤整合型新剂型制备技术及其生产方法 |
CN104800760A (zh) * | 2015-04-30 | 2015-07-29 | 青岛辰达生物科技有限公司 | 一种治疗肝胃郁热型反流性食管炎的中药组合物 |
-
2023
- 2023-06-30 CN CN202310788417.8A patent/CN116712523B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102580019A (zh) * | 2011-01-14 | 2012-07-18 | 天津市中宝制药有限公司 | 一种治疗反流性食管炎的中药组合物 |
CN102847090A (zh) * | 2011-06-30 | 2013-01-02 | 苏州知微堂生物科技有限公司 | 一种旋复代赭汤整合型新剂型制备技术及其生产方法 |
CN104800760A (zh) * | 2015-04-30 | 2015-07-29 | 青岛辰达生物科技有限公司 | 一种治疗肝胃郁热型反流性食管炎的中药组合物 |
Non-Patent Citations (1)
Title |
---|
旋覆代赭汤临床新用;刘莉;赵淑斌;;山西中医;25(09);第58页右栏 2.反流性食管炎 * |
Also Published As
Publication number | Publication date |
---|---|
CN116712523A (zh) | 2023-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104998197A (zh) | 一种用于治疗肝癌的中药组合物 | |
CN103055257B (zh) | 治疗慢性胃炎的中药及其制备方法 | |
CN113209194B (zh) | 一种治疗慢性胃炎的组合物及其制备方法和应用 | |
CN116712523B (zh) | 一种治疗中虚气逆型反流性食管炎组合物及其制备方法 | |
CN112717113B (zh) | 一种治疗过敏性鼻炎中药组合物及其膏方和应用 | |
CN113876872A (zh) | 一种治疗反流性食管炎的配方 | |
CN113797294A (zh) | 一种治疗萎缩性胃炎的药物组合物及制备方法 | |
CN104258224A (zh) | 一种治疗肺肾阴虚型慢性支气管炎的五味子口服液及其制备方法 | |
WO2015149391A1 (zh) | 一种治疗慢性肠炎的中药制剂及其制备方法 | |
CN104257871B (zh) | 用于治疗湿热毒蕴型急性网状淋巴管炎的药物组合物及其制备方法 | |
CN108066731B (zh) | 一种治疗Barrett食管的中草药组合物及其制备方法和应用 | |
CN106237206A (zh) | 一种治疗肿瘤的中药制剂及其制备方法 | |
CN105012789A (zh) | 治疗宫颈癌的组合物及其制备方法 | |
CN105412679A (zh) | 一种治疗肺脓肿的中药制剂及其制备方法 | |
CN105709005A (zh) | 一种乳康丸 | |
CN106806680A (zh) | 生白方中药饮片组合制剂、制备方法及组合包装 | |
CN104825977A (zh) | 一种治疗脾虚伤食型产后伤食的中药组合物及制备方法 | |
CN105616576A (zh) | 慢性痢疾活血止痢稠膏 | |
CN113975361A (zh) | 一种含砂仁油的中药软胶囊及其制备方法 | |
CN104800457A (zh) | 一种治疗胃癌的软坚散结剂及制法 | |
CN114949136A (zh) | 一种治疗慢性咽炎的中药组合物及其制备方法和应用 | |
CN104398627A (zh) | 食管癌以毒攻毒药剂及制备方法 | |
CN104491264A (zh) | 治疗食道癌的清热解毒剂及制备方法 | |
CN113181335A (zh) | 一种治疗支气管哮喘寒饮蕴肺证的穴位敷贴及其制备方法 | |
CN113368059A (zh) | 一种治疗幽门螺旋杆菌肝胃不合的中药干粉及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |